Travere Therapeutics Stock (NASDAQ: TVTX)

Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

Lattice Semiconductor

News

Intraday Update

Markets

Movers

Trading Ideas

ATEX

INTC

LSCC

MYTE

RLGT

SLQT

TVTX

Lattice Semiconductor, SelectQuote, Radiant Logistics And Other Big Stocks Moving Higher On Tuesday

NTRA


The healthcare sector is vast and includes everything from massive legacy companies including UnitedHealth Group Inc. (NYSE:UNH) and McKesson Corp. (NYSE:MCK) to tiny upstart pharmaceuticals firms. Investors looking to

3 Under-the-Radar Healthcare Companies

jim-cramer-shutter4

PLTR

Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black &amp; Decker.

Jim Cramer Says &#39;Hold On&#39; To Palantir, &#39;Let Them Walk It Up&#39;; Warns That Travere Therapeutics Is Losing A &#39;Ton Of Money&#39;

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics Inc

Health Care

Press Releases

Travere Therapeutics to Present at Upcoming Investor Conferences

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Travere Therapeutics Provides Corporate Update and 2025 Outlook

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Earnings

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Apogee Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Denali Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

ImmunityBio

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MannKind

Novavax

Soleno Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Comments

Travere Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga